Patent Expires For Popular Drug Lipitor

Wednesday, November 30, 2011

The 10 million Americans who take Lipitor to deal with their high cholesterol are about to get some good news. The 20 year patent on the blockbuster prescription drug expires Wednesday, creating an opening for other companies to manufacture cheaper, chemically identical generic versions of the drug. Two companies have products coming out on the market to entice the 3.5 million users of Lipitor away. But Pfizer, the makers of Lipitor − which derives almost a fifth of its revenue from $11 billion in sales of the drug — has its own plan for keeping patients on the name brand.

Michael Kleinrock, director of research development at the IMS Institute for Health Care Informatics, a company that does market research for the health care industry, discusses Pfizer's strategy. Harriet Washington, author of "Deadly Monopolies: The Shocking Corporate Takeover of Life Itself — And the Consequences for Your Health and Our Medical Future," examines the ethics of Pfizer's plan.


Michael Kleinrock and Harriet Washington

Comments [1]


Of course, the money mongers will now reduce the cost to generic prices and instead of being ashamed of their initial greed, happily accept a more feasible price! And all profits made above and beyond that threshold should be returned to customer and insurance pockets. Greed, the pharma force!!!!!

Nov. 30 2011 08:51 AM

Leave a Comment

Register for your own account so you can vote on comments, save your favorites, and more. Learn more.
Please stay on topic, be civil, and be brief.
Email addresses are never displayed, but they are required to confirm your comments. Names are displayed with all comments. We reserve the right to edit any comments posted on this site. Please read the Comment Guidelines before posting. By leaving a comment, you agree to New York Public Radio's Privacy Policy and Terms Of Use.